Background. With the development of sensitive tests to detect cytomegalovirus (CMV)
viremia, preemptive approaches become a reasonable alternative to general CMV …

Background Several anti-viral drugs have demonstrated efficacy in preventing
Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients. The recently …

Breakthrough cytomegalovirus (CMV) disease during valganciclovir prophylaxis is rare but
may cause significant morbidity and even mortality. In order to identify patients at increased …

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in
liver transplant recipients has not been established. We retrospectively compared the …

We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence
and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid …

Cytomegalovirus (CMV) is still a major pathogen in liver transplantation (LTX). The clinical
efficacy of prophylactic high‐dose acyclovir therapy (800 mg qid) was assessed for the …

Late-onset cytomegalovirus (CMV) disease, defined as CMV disease occurring after 3
months posttransplant is a significant complication with the use of prophylaxis, particularly in …

Cytomegalovirus (CMV) is an important cause of morbidity and mortality in liver transplant
recipients and several different strategies of CMV chemoprophylaxis are in practice. A cost …

OBJECTIVES: To assess the safety of a cytomegalovirus prophylaxis regimen using
selective low-dose valganciclovir. METHODS: Retrospective before–after comparison …

Background Cytomegalovirus (CMV) remains the most critical viral pathogen after kidney
transplantation (KTx). The universal prophylaxis, but not pre-emptive therapy, could avoid …